News

Investor News

November 30th, 2017
The Swedish Royal Technology Mission 2017 and His Majesty King Carl XVI Gustaf of Sweden visited Immunovia yesterday

LUND, Sweden ― The Swedish Royal Technology Mission 2017 and His Majesty King Carl XVI Gustaf of Sweden as the Guest of Honor visited yesterday, the 29th of November, 2017, CREATE Health Cancer Center and four of the most innovative companies at Medicon Village. The delegation of prominent political and industry leaders included Skånes County Governor Anneli Hulthen as well as IVA President Prof Tuula Teeri. Leif Johansson, the Presiding Officer of the Royal Institute of Technology was leading the delegation.

November 16th, 2017
World Pancreatic Cancer Day is today: If pancreatic cancer is found early, it saves lives

LUND, Sweden ―Today on World Pancreatic Cancer Day, pancreatic cancer remains to show one of the lowest survival rates among all major cancers. In nearly every country, pancreatic cancer is the only cancer with a single-digit five-year survival rate (2-9 percent). Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer, and an estimated 985 will die from the disease. It is estimated that by 2020, 418,000 new cases will be diagnosed globally.

November 13th, 2017 R
Immunovia will hold a Q3 report telephone conference on Monday Nov 13th

Mats Grahn, CEO, Immunovia, will hold a Q3 report telephone conference on Monday Nov 13th at 16:00 CET.

November 13th, 2017
World Pancreatic Cancer Day Sweden at 9.00 am (CET) on November 16, 2017

World Pancreatic Cancer Day Sweden – It’s About Time, an online event that will start at 9.00 am (CET) on November 16, 2017. Clinicians, pancreatic cancer patient organizations, survivors and their families from USA, Sweden, Spain and UK will talk in this online event about challenges, opportunities and how we can join forces to improve […]

November 10th, 2017 R
Immunovia Interim report, January-September 2017

“The important prospective studies for the pancreas test within the diabetes group (“PANDIA-1”) and the early symptoms group (“PANSYM-1”) have in discussions with clinical partners made progress for both PANDIA-1 and PANSYM-1. At the end of October, collection of blood samples began from patients with early symptoms at University College London Hospital. This was a very significant milestone for PANSYM-1. The retrospective, diabetes risk-group study based on the biobank from Region Skåne is also now under way.”

November 7th, 2017 R
Immunovia AB (Publ) nomination committee appointed for AGM 2018

According to the instruction that was adopted at the Immunovia AB (Publ) AGM April 25 2017, the nomination committee should consist of three members.

November 2nd, 2017 R
University College London Hospital starts the collection of blood samples to evaluate IMMray™ PanCan-d in symptomatic patients

University College London Hospital will assess Immunovia’s IMMray™ PanCan-d in 360 patients with symptoms suggestive of early pancreatic cancer

October 31st, 2017 R
Increase in share capital and number of shares in Immunovia

The share capital and number of shares in Immunovia AB (publ) has changed due to share warrants being exercised in the company.

·          The share capital has increased from SEK 840,902.95 to SEK 865,902.95.
·          The number of shares has increased by 514,000 to 17,318,059 shares.
·          The dilution amounts to 3.1%.

October 30th, 2017 R
Immunovia receives SEK4.9 Million grant from Swelife Accelerator Innovation Program

The grant supports completion of the development studies of IMMray™ PanCan-d, the first blood-based test for early stage pancreatic cancer to enable increased possibility of successful surgical intervention.

October 23rd, 2017 R
Immunovia signs major autoimmune biomarker discovery collaboration with Linköping University

Aim to develop next generation of autoimmune diseases diagnostics based on IMMray™ antibody array platform.

October 2nd, 2017
Immunovia AB on track regarding application for listing on Nasdaq Stockholm’s main market

As previously announced, the company’s preparations of internal processes to meet the requirements on Nasdaq Stockholm’s main market were expected to be completed in September for initiation of the formal listing process. This goal has been achieved and Nasdaq reviews and formal processes will now follow as planned with the goal to list the company on Nasdaq Stockholm’s main market.

September 26th, 2017 R
Management and employees of Immunovia subscribe for new shares by exercising warrants

Management and employees at Immunovia AB (publ) (”The Company”) have subscribed for 514,000 new shares in Immunovia AB (publ) by exercising 504,000 warrants of series 2014/2017 that were issued during the first quarter of 2014, and 10,000 warrants of series 2015/2018 that were issued during the second quarter of 2015. The new shares will raise […]

September 7th, 2017 R
Immunovia announces collaboration with Lund University Diabetes Centre for the early detection of pancreatic cancer in diabetes risk group

LUND, Sweden ― Immunovia AB is delighted to announce a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population. 

August 23rd, 2017 R
Immunovia Interim report, January-June 2017

“During Q2 we announced that we are establishing our American office in Boston. The head office for the US includes our own reference laboratory that complements our earlier collaboration with Knight Diagnostic Laboratories and gives us delivery capacity in both the east and west of the United States.”

“Another highlight for Immunovia during the quarter was the excellent results from the study of differentiation of Rheumatoid Arthritis (RA), Sjögren’s Syndrome and Systemic Vasculitis. These results complement the ones from the earlier differential study that we presented for SLE in Q1. They further confirm that our IMMrayTMplatform is generally applicable for many unsolved clinical problems within both cancer and autoimmunity while specifically strengthening our possibilities in the autoimmunity field.”

“During the quarter we announced that, together with Knight Cancer Institute at OHSU, we received a research grant from PanCAN, a patient advocacy group, to support a retroactive analysis of American patients who developed pancreatic cancer after being diagnosed with diabetes.”

August 18th, 2017
Immunovia invites to a conference call on August 23, 2017

Immunovia invites to a conference call in connection with reporting the half-year results 2017. The conference call will take place at 16:00 on August 23 and the result is expected to be published at 8:30 AM the same day.

July 17th, 2017 R
Leading expert on pancreatic cancer, Professor Stephen Pereira at University College London, joins Immunovia’s Scientific Advisory Board

LUND, Sweden ― Immunovia announced today that Professor Stephen Pereira, one of the globally leading experts in the diagnosis of early symptoms of pancreatic cancer and a multidisciplinary diagnostic center champion has been appointed to the company’s Scientific Advisory Board. Currently, Pereira is Professor of Hepatology & Gastroenterology at UCL, University College London, and an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and The Royal Free Hospital.  

June 30th, 2017 R
Immunovia together with Oregon Health and Science University awarded one of the Pancreatic Cancer Action Network 2017 Research Grants

LUND, Sweden ― On the 28th of June, it was announced that Pancreatic Cancer Action Network (PanCAN), the largest patient advocacy group in USA, in partnership with generous donors, awarded Prof. Brett Sheppard and Prof. Rosalie Sears from Oregon Health and Science University one of the Research grants for 2017 of a value of $ 250.000.

June 28th, 2017 R
Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston

LUND, Sweden ― Immunovia today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized.  This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilitating commercialization, covering marketing, sales and customer support.

June 21st, 2017 R
Immunovia’s IMMray™ presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy

LUND, Sweden – Immunovia today announced that they have completed the analysis of the three other autoimmune diseases included in the previously reported large, retrospective autoimmune disease study, performed in collaboration with Department of Immuntechnology, Lund University. The study included 315 blood samples and covered main autoimmune indications such as, Systemic Lupus Erythematosus Rheumatoid Arthritis (RA), Sjögren’s Syndrome, Systemic Vasculitis and healthy controls. For SLE, two sets of differential diagnosis data were previously reported March 7 2017.

June 16th, 2017 R
Immunovia AB announces timetable for listing on Nasdaq Stockholm’s main market

LUND, Sweden – The Board of Directors of Immunovia AB today announces timetable for the application for listing of the company’s shares on Nasdaq Stockholm’s main market. Immunova’s shares are currently traded on Nasdaq First North under the ticker IMMNOV.

June 13th, 2017 R
Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan

LUND, Sweden ― Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer.  Japanese Patent No. JP 6115801, is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test. 

April 25th, 2017 R
Immunovia Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299, har hållits den 25 april 2017 i Gamla Gästmatsalen på Medicon Village, Scheelevägen 2, Lund. Nedan följer en sammanfattning av de beslut som fattades.

April 20th, 2017 R
Immunovia Interim report, January-March 2017

“During the quarter we reported from a significant study that showed our ability to differentiate between SLE and other common autoimmune diseases. The very good results of the study, which indicated that SLE can be differentiated with 96% accuracy against a mix of healthy, rheumatoid arthritis, Sjögren’s disease and vasculitis patient samples, give us a […]

April 19th, 2017
Immunovia inbjuder till telefonkonferens den 20 april 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av första kvartalet 2017. Telefonkonferensen äger rum kl. 16:00 den 20 april och resultatet beräknas publiceras kl. 8:30 samma dag.

March 24th, 2017 R
IMMUNOVIA AB KALLAR TILL ÅRSSTÄMMA OCH PUBLICERAR ÅRSREDOVISNING FÖR RÄKENSKAPSÅRET 2016

Styrelsen i Immunovia AB (publ), org nr 556730-4299, kallar härmed till årsstämma. Datum:                                           25 april 2017 Tid:                                                   15.00 Plats:                                               Gamla Gästmatsalen, Inspira, Medicon Village, Scheelevägen 2, Lund Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 19 april 2017 och […]

March 7th, 2017 R
Final data from major Swedish study confirms that IMMray™ biomarker microarray differentiates SLE from other autoimmune diseases with 96% accuracy

LUND, Sweden: Immunovia today announced that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray™ blood-based biomarker signatures in differentiating SLE from three other main autoimmune diseases: rheumatoid arthritis, Sjögren disease and vasculitis. There is a clear clinical need for such a test since more than 50% of SLE patients are being initially misdiagnosed, mainly due to ambiguous laboratory test results.

February 22nd, 2017 R
Immunovia tillkännager genomförd blocktransaktion i bolagets aktier

 Befintliga och nya institutionella och professionella investerare förvärvar aktier genom en blocktransaktion.  Transaktionen genomfördes till priset av 95 kronor per aktie.  Säljande parter har förbundit sig till nya lock up-restriktioner fram till och med utgången av 2017. Immunovia tillkännagav idag en förändring i bolagets ägarstruktur. Totalt 400 000 aktier, motsvarande 2,4 procent av bolagets aktiekapital, såldes […]

February 15th, 2017 R
Immunovia Financial Statement 2016

2016 in Summary • Prospective validation study of the hereditary risk group for pancreatic cancer started as planned at the end of 2016. • IMMray™ PanCan–d validated in an American patient cohort. 96% accuracy confirmed for early detection of pancreatic cancer. • Collaboration with the US National Center Institute to focus on early onset diabetes […]

February 14th, 2017 R
Immunovia inbjuder till telefonkonferens den 15 februari 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2016. Telefonkonferensen äger rum kl. 16.00 den 15 februari och resultatet beräknas
publiceras kl. 08.00 samma dag.

February 13th, 2017 R
Immunovia presenterar vid Vator Securities Unicorn Summit

Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 7 mars 2017 på IVA i Stockholm, med start klockan 11.30.

January 16th, 2017 R
University of Michigan Pancreatic Cancer Center new partner in Immunovia’s global PANFAM-1 prospective validation study

LUND, Sweden, and Ann Arbor, USA ― Immunovia AB is pleased to announce that the University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating in the PANFAM-I prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals.

January 13th, 2017
Immunovia bjuder in till telefonkonferens tisdag 17/1 kl 16:00

Med anledning av gårdagens offentliggörande av studieresultaten där Immunovia kan påvisa att IMMray™ biomarkörsignatur kan särskilja Systemic Lupus Erythematosus (SLE) med 90 procents träffsäkerhet från andra autoimmuna sjukdomar, inbjuder Immunovia till telefonkonferens på tisdag 17 januari, kl 16:00.

January 12th, 2017 R
Immunovia announces first data exceeding 90% accuracy in distinguishing systemic lupus erythematosus (SLE) from other autoimmune diseases in new study

LUND, Sweden ― Immunovia today announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray™ biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an average accuracy exceeding 90%. These results are extremely encouraging because the symptoms of SLE mimic other rheumatic, autoimmune diseases leading to more than 50% of the patients being initially misdiagnosed, mainly due to ambiguous laboratory test results. It is estimated that as many as 5 million people suffer from SLE and it may take up to 3 years from symptoms appearing to diagnosis and treatment.

December 22nd, 2016
Immunovia Shareholder Newsletter Q4 2016

Dear Immunovia Shareholders,

With the end of the year approaching and many of you looking forward to a well-deserved Christmas and New Year celebration, we at Immunovia would also like you to join us in celebrating an unprecedented year which we are sure you would agree has more than surpassed expectations. In this newsletter, we would like to give you a summary of the milestones and highlights of a highly successful 2016 and the outlook for what is shaping up already to be an equally productive 2017. In particular 2016 was an exciting year as we started implementing Immunovia’s commercialization plan focussing on the goal of achieving reimbursement and national guideline status.

December 20th, 2016 R
Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.

December 9th, 2016 R
Immunovia announces collaboration with the renowned Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid

LUND, Sweden, and MADRID, Spain ― Immunovia AB is delighted to announce the addition of the leading Spanish research centre Ramon y Cajal Institute for Health Research (IRYCIS) to a global network of leading sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe that offer high risk pancreatic cancer screening programs. 

December 9th, 2016 R
Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Immunovia and NCI (National Cancer Institute), has in a memorandum of understanding agreed to collaborate towards a common goal of cancer biomarker development and validation, in particular regarding early detection of pancreatic cancer in the risk group of new onset diabetes over 50 years.

December 9th, 2016 R
Summary from the extraordinary general meeting of Immunovia

Extraordinary General Meeting of Immunovia AB (publ), 556730-4299, has been held in the confernce room ”Gamla Gästmatsalen”, House 302, Medicon Village, Scheelevägen 2, 223 63 Lund, December 9, 2016. Below is a summary of the resolutions of the extraordinary general meeting.

November 18th, 2016 R
Immunovia awarded 2016 Stars of Innovation Prize

Leading-edge healthcare diagnostics company making major progress in Europe.

November 16th, 2016 R
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)

Styrelsen i Immunovia AB (publ), org nr 556730-4299, kallar härmed till extra bolagsstämma. Datum:                                           2016-12-09 Tid:                                                   11.00 Plats:                                               Gamla Gästmatsalen, Hus 302, Medicon Village, Scheelevägen 2, 223 63 Lund Anmälan/rätt att delta på stämman  Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken lördagen den 3 december […]

November 15th, 2016
WORLD PANCREATIC CANCER DAY, LUND SWEDEN, November 17, 2016 – It’s About Time

Every day, more than 900 people around the world die from pancreatic cancer. Only 6 percent of the patients diagnosed with pancreatic cancer survive 5 years. According to a recent global survey, more than 60 percent of people know “almost nothing” about pancreatic cancer.

October 19th, 2016 R
Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee.

October 13th, 2016 R
Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016

Stars of Innovation nomination recognizes stellar performance since IPO

October 7th, 2016 R
Immunovia: Insiders transfer subscription rights free of charge

LUND, Sweden ― Within the framework of the ongoing rights issue at Immunovia AB (publ) (“the company “) Carl Borrebaeck and Christer Wingren, Chairman of the Board and Chief Technical Officer respectively at the company, have, on request from professional investors and in consultation with the company’s financial advisor Vator Securities, transferred all subscription rights received in the rights issue to named investors.

September 26th, 2016 R
Immunovia publishes prospectus regarding preferential rights issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia publishes prospectus regarding preferential rights issue

Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”).

Publication of prospectus
Immunovia’s prospectus, prepared in connection with the Rights Issue, has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus has today been published and is also available on the company’s web page http://immunovia.com/investors/ and the Company’s head office.

September 15th, 2016 R
The board of directors of Immunovia resolves on a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

The board of directors of Immunovia resolves on a directed and preferential right issue

September 14th, 2016 R
Immunovia intends to launch a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia intends to launch a directed and preferential right issue

Summary
Immunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares.

Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK 30 million with preferential right for the Company’s existing shareholders.

September 5th, 2016 R
Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer

The best chance to influence the survival of non-hereditary pancreatic cancer patients is to focus on early detection of cases in people aged over 50 who receive their first diagnosis of diabetes. There is now clear unanimity on this, and both public authorities and health institutes focused on the link between diabetes and pancreatic cancer are initiating research programmes on a large scale across several countries in order to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group.

August 24th, 2016 R
Immunovia Half-year report 2016

“Immunovia reached several important milestones in the first six months of 2016. Good results were obtained in the American pancreas study that was carried out in collabo­ration with Knight Cancer Institute. Presentations made at the key global conferences concerning pancreatic cancer were very well received. A specially strong Scientific Advisory Board has been recruited, and […]

August 17th, 2016 R
Immunovia invitation to a teleconference on 24 August 2016

Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same day

August 16th, 2016 R
Immunovia announces intention to apply for listing on Nasdaq Stockholm’s Main Market

The Board of Immunovia AB (publ) (“Immunovia” or the “Company”) today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm’s Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker.

July 15th, 2016 R
Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board

Extensive expertise in clinical tumor management and tumor biomarkers, will help accelerate pancreatic cancer diagnostic program

July 5th, 2016 R
World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology and Diagnostics at the University and Hospital Trust of Verona in Italy.

June 23rd, 2016 R
Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF.

May 31st, 2016 R
Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299 har hållits lokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund den 30 maj 2016. Nedan följer en sammanfattning av de beslut som fattades.

May 30th, 2016 R
96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort

Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer  

May 30th, 2016 R
Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer

Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancer

May 18th, 2016
Inbjudan till Immunovia Informationsmöte i Stockholm den 1 juni kl 17.30 med VD MatsGrahn och Styrelseordförande Carl Borrebaeck

Aktieägare som inte har möjlighet att deltaga på Immunovias bolagsstämma den 30 maj i Lund samt övriga intresserade hälsas välkomna till ett informationsmöte där VD Mats Grahn och Styrelseordförande Carl Borrebaeck informerar om bolagets utveckling under 2015 och därefter.

May 9th, 2016
IMMUNOVIA JOINS MORE THAN 40 GLOBAL PANCREATIC CANCER ORGANIZATIONS AT INAGURAL MEETING

World Pancreatic Cancer Coalition Aims to Raise Unprecedented Awareness for a Disease with the Lowest Survival Rate of Any Major Cancer.  

April 26th, 2016 R
Immunovia kallar till årsstämma 2016

Styrelsen i Immunovia AB (publ) har kallat  till årsstämma den 30 maj 2016. Stämman kommer att hållas kl 16.00 i samlingslokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund.

April 8th, 2016 R
Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer.

April 1st, 2016
NOTE about Immunovia and IMMray™ technology information on newswires and social media

Lund, Sweden – During the last months, Immunovia’s news and press releases have caught the attention of social media and journalists around the world. Due to the nature of the Internet, several articles have been published and will continue to be published not only by Immunovia chosen news channels but also by communities of independent […]

March 9th, 2016 R
Immunovia partners with leading healthcare consultingservices firm

Immunovia partners with leading healthcare consulting services firm to support market access of pancreatic cancer test in Germany
*
Immunovia announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray™ PanCan-d in Germany

March 8th, 2016
Immunovia launches Swedish website

LUND, Sweden ― Immunovia AB today introduces its website in Swedish as part of the efforts to grow its presence in the Scandinavian home markets. The company launched its global website one year ago and online reports show high total number of visitors from all around the world. However, since December last year, when the […]

February 29th, 2016 R
Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLE

February 24th, 2016 R
Immunovia Year-end report 2015

“In 2015 Immunovia took important steps toward commercialisation of the world’s first blood-based test for cancer diagnosis, IMMray™ PanCan –d. We were able to prove, with 96% accuracy, that our test can diagnose the early stages of pancreatic cancer. In the second half of the year we signed a comprehensive agreement with Knight Cancer Institute […]

February 10th, 2016 R
Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures

Immunovia initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for SLE also known as “lupus”. 

February 9th, 2016 R
Immunovia announces collaboration with Mount Sinai Health System to validate early detection blood test for pancreatic cancer

LUND, Sweden, and NEW YORK, USA ― Immunovia AB is pleased to announce that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting second half of 2016.

January 19th, 2016 R
Immunovia and the University of Liverpool enter into a collaboration in a prospective clinical study

LUND, Sweden, and Liverpool, UK ― Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study. In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical Research Unit, based at the Royal Liverpool University Hospital. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half of 2016.

December 18th, 2015 R
White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

LUND, Sweden ― In this White Paper, Immunovia summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates from 4-6% to 50-60%.

December 3rd, 2015 R
IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples

Largest ever study for diagnosing pancreatic cancer paves way for early intervention to significantly improve survival rates.

December 2nd, 2015 R
Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Trading in Immunovia AB’s shares (IMMNOV) commenced yesterday on Nasdaq First North in Stockholm. At closing the share price had surged 60 percent compared to the introduction price. The interest among investors was high. The trading turnover was SEK 28.5 million during the day, thus setting a new record among comparable First North listings during 2015.

November 26th, 2015
Immunovia approved for trading on Nasdaq First North as of December 1st, 2015

Immunovia AB (publ) has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. Immunovia is a Swedish research company that has developed a new method for using a blood test to diagnose pancreatic cancer. With Immunovia’s test, diagnosis can be made earlier which substantially enhances the possibilities to treat the cancer. A new share issue of SEK 60 million before issue costs have been carried out before introduction on First North.

October 5th, 2015
Immunovia, OHSU collaborating on early detection test for pancreatic cancer

LUND, Sweden, and PORTLAND, Oregon ― Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.